# PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Oncology  
**Manuscript NO:** 66730  
**Title:** The tsunami of immunotherapy reaches mesothelioma  
**Provenance and peer review:** Invited Manuscript; Externally peer reviewed  
**Peer-review model:** Single blind  
**Reviewer’s code:** 05258171  
**Position:** Peer Reviewer  
**Academic degree:** MD  
**Professional title:** Doctor  
**Reviewer’s Country/Territory:** China  
**Author’s Country/Territory:** Spain  
**Manuscript submission date:** 2021-04-03  
**Reviewer chosen by:** AI Technique  
**Reviewer accepted review:** 2021-04-12 03:27  
**Reviewer performed review:** 2021-04-20 03:06  
**Review time:** 7 Days and 23 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ ] Grade A: Excellent</th>
<th>[ ] Grade B: Very good</th>
<th>[Y] Grade C: Good</th>
<th>[ ] Grade D: Fair</th>
<th>[ ] Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Language quality</td>
<td>[ ] Grade A: Priority publishing</td>
<td>[Y] Grade B: Minor language polishing</td>
<td>[ ] Grade C: A great deal of language polishing</td>
<td>[ ] Grade D: Rejection</td>
<td></td>
</tr>
<tr>
<td>Conclusion</td>
<td>[ ] Accept (High priority)</td>
<td>[ ] Accept (General priority)</td>
<td>[ ] Minor revision</td>
<td>[Y] Major revision</td>
<td>[ ] Rejection</td>
</tr>
<tr>
<td>Re-review</td>
<td>[Y] Yes</td>
<td>[ ] No</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peer-reviewer</td>
<td>Peer-Review: [Y] Anonymous</td>
<td>[ ] Onymous</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SPECIFIC COMMENTS TO AUTHORS

In this manuscript, Mielgo-Rubio et.al. reviewed the recent studies on the immunotherapy of mesothelioma. The authors focused on the results of two phase III clinical trials, which represent a major landmark in the treatment of MPM. The following needs to be addressed:

1. Please consider replacing all tables with a three-line tables, and improve Table 2 to make its content more clear. References should be included in the tables.

2. Please try to summarize the advantages of nivolumab and ipilimumab as a new first-line treatment strategy compared to previous regimens. Please try to merge it into a table.

3. This article introduces the therapeutic effect and adverse effects of doublet chemotherapy with cisplatin and pemetrexed on mesothelioma, as well as the effect of novel nivolumab and ipilimumab immunotherapy. However, the adverse effect of nivolumab and ipilimumab immunotherapy was not introduced.

4. In the treatment of malignant mesothelioma targeting PD-L1, nivolumab and ipilimumab had shown different results. In addition, how does the nivolumab and ipilimumab act as an inhibitor on the PD-1/PDL-1 pathway? Please try to explain these reasons.